MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease

    A.M. Rizos, P. Martinez-Martin, P. Reddy, M. Silverdale, K. Ashkan, A. Antonini, D. Calandrella, P. Odin, T. Henriksen, N. Bryndum, A. Glad, M.G. Kramberger, Z. Pirtošek, M. Trošt, T. van Laar, R. Katzenschlager, H.S. Dafsari, L. Timmermann, A. Storch, H. Reichmann, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

    Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…
  • 2016 International Congress

    Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

    N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To review the clinical use of a newer extended-release levodopa preparation in 50 consecutive patients with PD experiencing motor fluctuations on immediate-release levodopa. Background:…
  • 2016 International Congress

    Chronic levodopa treatment accelerates the disorders of circadian rhythm in 6-OHDA induced Parkinson’s disease model

    S. Li, Y. Wang, W. Liu, D. Lv, C. Liu (Suzhou, People's Republic of China)

    Objective: We aimed to study the effect of levodopa on circadian rhythms in 6-OHDA lesioned rats, and to clarify whether the disturbance of the circadian…
  • 2016 International Congress

    Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

    R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)

    Objective: To prospectively investigate the response to acute levodopa challenge in patients with advanced Parkinson's disease (PD) never treated before. Background: Pathophysiological mechanisms underlying motor…
  • 2016 International Congress

    Phenotypic spectrum and longitudinal outcome of Parkinson’s disease patients with psychosis

    M.S. Nanjunda Swamy, M.M. Abbas, S.T. Govindappa, P. Basu, R. Ramanathan, U.B. Muthane (Bangalore, India)

    Objective: We studied the phenotypic characteristics of psychosis in PD patients, their associated risk factors and assessed their long term outcome. Background: Psychosis in PD…
  • 2016 International Congress

    Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

    S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)

    Objective: To assess the frequency of neuropathy and its neurophysiological characteristics in orally and levodopa/carbidopa intestinal gel (LCIG) treated patients with advanced idiopathic Parkinson´s disease…
  • 2016 International Congress

    Motor phenotype classification in moderate to advanced PD: Data from the BioFIND study

    L. Luo, H.F. Andrews, J.G. Goldman, R.N. Alcalay, T. Xie, P. Tuite, C. Henchcliffe, P. Hogarth, A. Amara, S. Frank, A. Rudolph, C. Casaceli, K. Gwinn, M. Sutherland, C. Kopil, L. Vincent, M. Frasier, U.J. Kang (New York, NY, USA)

    Objective: To evaluate the validity of motor phenotype classification in response to dopaminergic agents in moderate to advanced Parkinson's disease (PD) patients enrolled in the…
  • 2016 International Congress

    Efficiency of carotid endarterectomy in vascular parkinsonism in patients with stenotic carotid artery disease

    M. Ataniyazov, G. Rakhimbaeva, K. Ataniyazova (Tashkent, Uzbekistan)

    Objective: Primary aim of investigation was to evaluate the effectiveness of carotid endarterectomy (CEA) in patients with vascular parkinsonism (VP) with stenotic lesions of carotid…
  • 2016 International Congress

    The influences of STN-DBS and levodopa on cardiovascular autonomic function in patients with Parkinson’s disease: Evaluated by trigonometric regressive spectral analysis

    K. Li, M. Wolz, R. Haase, H. Reichmann, T. Ziemssen (Dresden, Germany)

    Objective: To explore the effects of STN-DBS and levodopa on cardiovascular autonomic function in PD. Background: Cardiovascular autonomic dysfunction has been shown in patients with…
  • 2016 International Congress

    Changes in serum amino acid levels with progression of Parkinson’s disease

    M. Figura, K. Kusmierska, E. Bucior, S. Szlufik, D. Koziorowski, Z. Jamrozik, A. Friedman, P. Janik (Warsaw, Poland)

    Objective: The purpose of this study was to analyze changes in serum amino acid profile with progression of Parkinson's disease (PD). Background: PD is a…
  • « Previous Page
  • 1
  • …
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley